KYTX vs. SNDL, TKNO, CKPT, ERAS, HUMA, CDTX, CYRX, ARCT, OLMA, and ITOS
Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include SNDL (SNDL), Alpha Teknova (TKNO), Checkpoint Therapeutics (CKPT), Erasca (ERAS), Humacyte (HUMA), Cidara Therapeutics (CDTX), Cryoport (CYRX), Arcturus Therapeutics (ARCT), Olema Pharmaceuticals (OLMA), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry.
Kyverna Therapeutics vs.
SNDL (NASDAQ:SNDL) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.
Kyverna Therapeutics has a net margin of 0.00% compared to SNDL's net margin of -12.11%. SNDL's return on equity of -8.27% beat Kyverna Therapeutics' return on equity.
SNDL received 130 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. Likewise, 71.94% of users gave SNDL an outperform vote while only 61.11% of users gave Kyverna Therapeutics an outperform vote.
Kyverna Therapeutics has lower revenue, but higher earnings than SNDL. SNDL is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kyverna Therapeutics had 10 more articles in the media than SNDL. MarketBeat recorded 14 mentions for Kyverna Therapeutics and 4 mentions for SNDL. SNDL's average media sentiment score of 1.35 beat Kyverna Therapeutics' score of 0.83 indicating that SNDL is being referred to more favorably in the media.
SNDL currently has a consensus target price of $3.63, indicating a potential upside of 173.58%. Kyverna Therapeutics has a consensus target price of $18.33, indicating a potential upside of 695.37%. Given Kyverna Therapeutics' higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than SNDL.
18.1% of Kyverna Therapeutics shares are held by institutional investors. 22.0% of Kyverna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
SNDL has a beta of 3.68, indicating that its stock price is 268% more volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500.
Summary
Kyverna Therapeutics beats SNDL on 10 of the 18 factors compared between the two stocks.
Get Kyverna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kyverna Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KYTX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy KYTX Stock Free KYTX Stock Alerts